ClinicalTrials.Veeva

Menu

CD133 Transplantation to Generate Oocytes in Poor Ovarian Reserve

L

La Fe University and Polytechnic Hospital

Status

Withdrawn

Conditions

Ovarian Reserve

Treatments

Procedure: CD133+ cells transplantation into ovarian artery of one ovary

Study type

Interventional

Funder types

Other

Identifiers

NCT01966536
Neofol2013

Details and patient eligibility

About

Women delay maternity and, as a consequence, available oocyte number and their quality decrease (9-18% of all IVF patients). Different treatment protocols have been developped nevertheless none of them optimal: the number of oocytes retrieved depends on the present ones. New generation of oocytes and follicles has been defended by some authors and bone marrow seems to be involved. What seems crucial is the niche that produces paracrine signals able to activate dormant cells and to attract undifferentiated cells from other tissues (homing). This phenomenon has been described by our group in other human reproductive tissues like endometrium. The purpose of the study is to improve ovarian reserve in unfertile women with poor ovarian reserve by means of bone marrow protective capacity.

CD133+ cells obtained from bone marrow will be delivered into the ovarian artery allowing them to colonize ovarian niche.

The study hypothesis is that CD133+ cells will improve ovarian reserve differentiating themselves into germ cells or, more likely, stimulating the niche to activate dormant follicles.

Sex

Female

Ages

18 to 40 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • < or= 40 years old
  • FSH<15UI/L
  • poor ovarian response after controlled ovarian stimulation with conventional doses (<3 oocytes) or two episodes of poor ovarian response after ovarian stimulation with maximal doses even if young or normal ovarian reserve study.
  • Antral follicle count>2
  • >1 antral follicle in the perfunded ovary
  • AMH between 0,5 and 1pmol/L
  • regular menstrual bleeding each 21-35 days
  • To be candidate to autologous hematopoietic progenitors transplantation

Exclusion criteria

  • Ovarian endometriosis
  • Anovulation
  • Any ovarian surgery considered risk factor of low ovarian response.
  • Genetic factors associated to low ovarian response (Turner syndrome, FMR1 mutations...)
  • Adquired conditions determining low response (chemotherapy, radiotherapy...)
  • BMI > or = 30kg/m2
  • Allergie to iodine
  • Kidney failure

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

0 participants in 1 patient group

Poor ovarian reserve
Experimental group
Description:
Autologous transplantation of CD133+ cells into ovarian artery
Treatment:
Procedure: CD133+ cells transplantation into ovarian artery of one ovary

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems